Checkpoint Therapeutics Inc (CKPT) Cotización

Volume is impressive today !! 

Not sure but it has bounced back from the Nov 5 lows. Chart looks like more upward movement expected and of course we are expecting FDA decision before the end of the year. It does seem like with their cash position and wherewithal that they would want to license the drug to BP or sell entirely to BP and have seen a poster on ST suggest the company has stated that they would be looking for such, but I can't find those statements from the company on their website. If you are aware of their intention to partner or sell the drug or themselves I would appreciate a link.

Just my opinion, but if we rally into the decision and even if it is positive I think the stock would sell off if no news on some kind of a deal.

Wonder why the tanking today 

CKPT anew 52/week high

Anyone else holding shares here ??!

CKPT.....................................https://stockcharts.com/h-sc/ui?s=CKPT&p=W&b=5&g=0&id=p86431144783

Seems 3 bucks is the resistance

CKPT...............................https://stockcharts.com/h-sc/ui?s=CKPT&p=W&b=5&g=0&id=p86431144783

Can we break 3 soon ???

CKPT under $3

CKPT under $3

Anyone holding here ?? Very quiet board .

Resubmission on the way !!

Waking up here ?? Any shareholders out there ??

CKPT......................................https://stockcharts.com/h-sc/ui?s=CKPT&p=W&b=5&g=0&id=p86431144783

Seriously

Dead money for quite a while. Maybe forever.

Is this drug and company done ????

CKPT under $2

CKPT 10Q due March 7

CKPT did a reverse split in the fairly recent past. I don't think that was in anticipation of anything specific other than selling additional shares in the future to raise money until they can generate some revenue. They were going to be selling shares whether or not they received the CRL. CRL just means they are going to be selling a LOT more shares than if they wouldn't have received it.

So did investors get a 'gift'?
Just heard about CKPT after the CRL came out. First comment is, resolution of the CRL could take longer than folks expect, just went thru it with CRMD and they got 2 CRLS due to the manufacturers QA issues (4 frigging years for the fda to agree to the 'fixes' and all the while the manufacturers were ALLOWED to continue operations under the fda umbrella, someone explain that one)

Anyways, so looking into CKPT, like the low share count, don't like the low cash on hand cause can only read it to mean, thanks to the delay, they will likely need to conduct a cash raising operation (ATM or flat out secondary). CRMD had to do this and it really cut their target price down.

So, just thought I would check in, see what folks are saying, and quite frankly, a bit surprised given its a cancer related treatment, given how the market is pricing so many bios as if they are selling gold, that CKPT was where it was on the share price..

But going to be studying their trial analysis, how good they see it working. And really tired of the fda holding up drug approvals for drugs that CAN/WOULD help save lives vs delaying the approval especially if it worked. Now I wouldn't be as 'upset' at the fda if as in this case, they tell the manufacturer, since you are bad enough for us not to approve a potential life saving drug, your operations are totally suspended.
Otherwise, to me, the fda has its priorities screwed up.. when it allows operations to continue.. but puts a life saving drug into limbo land.. again, CRMD has something going for it, hell of a lot better than the current standard of care, but was delayed 4 frigging years over QA issues.

Good luck

Stupid

Wouldn’t mind seeing a partner for launch !!

Always a concern with start up biomeds

Chart must look pretty good here . I wonder if another offering is coming ??

The positives continue

Patent news is cool.

Been awhile so lets update the chart

Let’s make a run into approval !!

CKPT under $2

CKPT new 52 week low

CKPT https://www.tipranks.com/news/blurbs/b-riley-financial-sticks-to-their-buy-rating-for-checkpoint-therapeutics-ckpt

CKPT https://www.tipranks.com/news/blurbs/lake-street-keeps-their-buy-rating-on-checkpoint-therapeutics-ckpt

ckpt https://www.tipranks.com/news/blurbs/b-riley-financial-sticks-to-their-buy-rating-for-checkpoint-therapeutics-ckpt

Biologics License Application currently under review by U.S. FDA; PDUFA goal date of January 3, 2024

WALTHAM, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced new, longer-term data for cosibelimab from its pivotal studies in locally advanced and metastatic cutaneous squamous cell carcinoma (“cSCC”). These results demonstrate a deepening of response over time, resulting in substantially higher complete response rates than previously reported. Furthermore, responses continue to remain durable over time with the median duration of response not yet reached in either group. Results determined by independent central review by treatment group were as follows:


Parametera Locally Advanced cSCC
(n=31) Metastatic cSCC
(n=78)
Data cutoff Mar 2022 Jan 2023 Nov 2021 Jan 2023
Objective response rate
(95% confidence interval) 55%
(36%, 73%) 55%
(36%, 73%) 47%
(36%, 59%) 50%
(39%, 62%)
Complete response rate 10 % 23 % 8 % 13 %
Partial response rate 45 % 32 % 39 % 37 %
Response ongoing 82 % 82 % 73 % 69 %
Median duration of response Not reached Not reached Not reached Not reached
a As assessed by independent central review.

“We are excited to see the substantial increases in the rate of patients experiencing a complete response of their cSCC tumors with further cosibelimab treatment in both our locally advanced and metastatic pivotal trials,” said James Oliviero, President and Chief Executive Officer of Checkpoint. “We believe cosibelimab’s strong efficacy and response durability are driven by its unique two-fold mechanism of action in which cosibelimab binds to PD-L1 with sustained high target tumor occupancy to reactivate the body’s T-cell anti-tumor response, with the addition of a functional Fc domain to activate the body’s natural killer immune cells to induce antibody-dependent cell-mediated cytotoxicity of tumor cells, resulting in a powerful one-two punch to eradicate tumors. We expect this dual mechanism of action to benefit not just immunocompetent patients, but also the large number of difficult-to-treat patients with immunosuppressive conditions or taking immunosuppressive medications who continue to suffer poor outcomes with currently available treatments.”

Updated safety data across 247 patients enrolled and treated with cosibelimab in all cohorts of the ongoing study remain consistent with those previously reported, with only 2% of patients experiencing a severe immune-related adverse event (“irAE”) and less than 1% of patients discontinuing treatment due to an irAE of any severity, both substantially lower than the rates observed with currently approved immunotherapies.

Mr. Oliviero continued, “Unlike PD-1 inhibitors, cosibelimab does not interrupt the body’s PD-1/PD-L2 pathway, which we believe results in cosibelimab’s low rates of autoimmunity. We believe cosibelimab’s favorable safety profile should position the product as the preferred immunotherapy of oncologists for the large number of high-risk cSCC patients, such as those with solid organ transplants or autoimmune disease, upon its potential launch early next year. If our Biologics License Application (“BLA”) is approved in the coming months, based on its unique mechanism of action and compelling efficacy and safety profile, we believe cosibelimab, as a differentiated and possibly best-in-class treatment, has the potential to become the market leading immunotherapy for patients with cSCC, which we estimate to be a $1.6 billion annual U.S. market opportunity.”

In January 2023, Checkpoint submitted a BLA to the U.S. Food and Drug Administration (“FDA”) seeking approval of cosibelimab as a treatment for patients with metastatic cSCC or locally advanced cSCC who are not candidates for curative surgery or radiation. The application is filed and under review with a Prescription Drug User Fee Act (“PDUFA”) goal date of January 3, 2024.

Checkpoint plans to present these updated results at an upcoming medical conference.

We can only hope !!!

Does that $10 million get them to PDUFA? Seems like chump change. I'm guessing they are hoping they can raise some more money once the stock starts to push up as PDUFA gets closer.

CKPT............................https://stockcharts.com/h-sc/ui?s=CKPT&p=W&b=5&g=0&id=p86431144783

CKPT.......................https://stockcharts.com/h-sc/ui?s=CKPT&p=W&b=5&g=0&id=p86431144783

CKPT.....................https://stockcharts.com/h-sc/ui?s=CKPT&p=W&b=5&g=0&id=p86431144783

This stock sure is volatile!!

Yeah , especially with the rise in stock price

Looks to me like they will have to do another stock offering. I think they have enough cash to last until June.

Market still only 80 million

Do we think another stock offering here soon ?? I’m sure they could use the cash

a recent holding split... medi wound, and now up 800%. sold before the split and did not buy back in. made some bucks but really missed out on the upswing.

Good point to remember. Big moves are quite possible. And anything is possible especially for the real big time insiders. Unfair to have such competition I say.

https://www.theblaze.com/news/moderna-neglected-to-share-damning-data-about-its-new-booster-shot

When you think about it, our market cap is still tiny !!!

Yeah , just hope we hold on to some of the gains !!!